RJA
XERS icon

Raymond James & Associates’s Xeris Biopharma Holdings XERS Stock Holding History

Raymond James & Associates’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$120K Buy
+42,062
New +$108K ﹤0.01% 3759
2022
Q1 		– Sell
-11,300
Closed -$33K – 4287
2021
Q4 		$33K Buy
+11,300
New +$24.4K ﹤0.01% 3989
2021
Q3 		– Sell
-92,900
Closed -$378K – 4273
2021
Q2 		$378K Buy
+92,900
New +$355K ﹤0.01% 3277
2020
Q4 		– Sell
-18,515
Closed -$110K – 3890
2020
Q3 		$110K Buy
+18,515
New +$74K ﹤0.01% 3365

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Raymond James & Associates's XERS Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Xeris Biopharma Holdings (XERS) in Q3 2024: 42,062 shares worth $120K. The stake represents ﹤0.01% of the portfolio and ranks #3759 among its holdings. This is a return to the name: Raymond James & Associates previously reported a position in XERS as recently as Q4 2021.

Raymond James & Associates first reported a position in XERS in Q3 2020 and has held it in 4 quarters since. The position peaked at $378K in Q2 2021. 144 funds tracked by Wall St. Rank hold XERS as of Q3 2024.

  • Raymond James & Associates held 42,062 shares of Xeris Biopharma Holdings worth $120K as of Q3 2024.
  • Xeris Biopharma Holdings was a new Raymond James & Associates position in Q3 2024.
  • Xeris Biopharma Holdings made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3759 holding.
  • Raymond James & Associates first reported a position in Xeris Biopharma Holdings in Q3 2020 and has held it in 4 quarters since.
  • Raymond James & Associates's Xeris Biopharma Holdings position peaked at $378K in Q2 2021.
  • 144 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.